Travis Davis, MD
Internal Medicine · Clermont, FLNPI 1669590477
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $895 and has fallen 74.6% since, to $227 in 2025.
Across 245 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$588
- GSK$575
- AstraZeneca$397
- Novo Nordisk$397
- Boehringer Ingelheim$248
- Exact Sciences$173
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,974100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 38 | $588 |
| GSK | 36 | $575 |
| AstraZeneca | 23 | $397 |
| Novo Nordisk | 25 | $397 |
| Boehringer Ingelheim | 16 | $248 |
| Exact Sciences | 10 | $173 |
| Amgen | 9 | $173 |
| Novartis | 10 | $162 |
| AbbVie(2 entities) | 9 | $153 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $152 |
| Dexcom, Inc. | 8 | $132 |
| Abbott | 5 | $127 |
| Bayer | 7 | $106 |
| Pfizer | 8 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Merck | 4 | $47 |
| Shield Therapeutics Inc | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Insmed, Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Lundbeck LLC | 1 | $23 |
| Exeltis, USA Inc. | 1 | $21 |
| Cranial Technologies, Inc | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,974 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 13 | $92,836 |
| JardianceEmpagliflozin | 97 | $80,790 |
| TrulicityDulaglutide | 62 | $67,075 |
| OzempicSemaglutide | 52 | $48,967 |
| MounjaroTirzepatide | 38 | $45,975 |
| FarxigaDapagliflozin Propanediol | 53 | $42,948 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $41,720 |
| RybelsusSemaglutide | 37 | $34,776 |
| EliquisApixaban | 27 | $24,370 |
| JanuviaSitagliptin Phosphate | 16 | $22,277 |
| XareltoRivaroxaban | 19 | $20,053 |
| LinzessLinaclotide | 33 | $18,147 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $14,187 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $13,674 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $13,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $588 | $113,049100 claims |
| AbbVieHumira(Cf), Linzess | $153 | $110,98346 claims |
| Novo NordiskOzempic, Rybelsus | $397 | $83,74389 claims |
| Boehringer IngelheimJardiance | $248 | $80,79097 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $397 | $57,13568 claims |
| PfizerEliquis, Premarin | $95 | $29,74245 claims |
| MerckJanuvia | $47 | $22,27716 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $575 | $22,18436 claims |
| Johnson & JohnsonXarelto | $18 | $20,05319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Clermont
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.